http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017508836-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99 |
| filingDate | 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017508836-A |
| titleOfInvention | Carboxylated derivatives of glucosaminoglycans and use as drugs |
| abstract | The present invention relates to a glucosaminoglycan derivative having heparanase inhibitory activity and antitumor activity and having a carboxylate group at the 2-position and 3-position of at least a part of a glucosaminoglycan residue, and a method for preparing the same . The glucosaminoglycan derivatives of the present invention are produced starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two-step oxidation. The The first oxidation converts the adjacent diol and optionally the adjacent OH / NH 2 of the glucosaminoglycan residue to an aldehyde, and the second oxidation converts the dialdehyde to a carboxylate group. The first oxidation is preferably one that causes cleavage of the C 2 -C 3 bond in the ring of the oxidizable residue. The invention further relates to a method for preparing said glucosaminoglycan derivative, and further to its use as an active raw material of a drug. Furthermore, the present invention relates to a pharmaceutical composition comprising a di / tricarboxylated heparin derivative as an active agent. [Selection] Figure 1 |
| priorityDate | 2013-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.